Barenfanger J, Short M A, Groesch A A
Microbiology, Pathology Department, Memorial Medical Center, Springfield, Illinois 62781, USA.
J Clin Microbiol. 2001 Aug;39(8):2823-8. doi: 10.1128/JCM.39.8.2823-2828.2001.
Studies have shown benefits to patients from improved interventions involving antimicrobial therapy. The purpose of the present study was to evaluate prospectively the impact of improved interventions by (i) the use of TheraTrac 2, a computer software program which electronically links susceptibility testing results immediately to the pharmacy and alerts pharmacists of potential interventions, and (ii) the education of pharmacists involving microbiologic topics. The study group had the new intervention program. The control group had interventions performed the way that they had previously been done by manually reviewing hard copies of susceptibility testing data. In a 5-month period, all inpatients whose last names began with A to K were the study group; inpatients whose last names began with L to Z were controls. Three analyses were done; one analysis (analysis A) involved only patients with interventions, one analysis (analysis B) involved all patients for whom antimicrobial testing was done and who were matched for diagnosis-related groups (DRGs), regardless of whether an intervention occurred, and one analysis (analysis C) involved these DRG-matched patients by using severity-adjusted data. In analysis A, the study group had a 4.8% decreased rate of mortality, an average of a 16.5-day decreased length of stay per patient, and $20,886 decreased variable direct costs per patient. None of these differences was statistically significant. In analysis B, the study patients had a 1.2% higher mortality rate (P = 0.741), an average of a 2.7-day decreased length of stay per patient (P = 0.035), and $2,626 decreased variable direct costs per patient (P = 0.008). In analysis C, the study patients had a 1.4% lower mortality rate, a 1.2-day decreased length of stay per patient, and $1,466 decreased variable direct costs per patient. In conclusion, the institution of this program caused substantial cost savings.
研究表明,改进抗菌治疗干预措施对患者有益。本研究的目的是前瞻性评估以下改进干预措施的影响:(i)使用TheraTrac 2,这是一种计算机软件程序,可将药敏试验结果立即电子链接到药房,并提醒药剂师潜在的干预措施;(ii)对药剂师进行微生物学主题教育。研究组采用新的干预方案。对照组的干预措施是按照以前的方式进行,即人工查阅药敏试验数据的硬拷贝。在5个月的时间里,所有姓氏以A到K开头的住院患者为研究组;姓氏以L到Z开头的住院患者为对照组。进行了三项分析;一项分析(分析A)仅涉及接受干预措施治疗的患者,一项分析(分析B)涉及所有进行了抗菌检测且诊断相关组(DRG)匹配的患者,无论是否进行了干预,一项分析(分析C)通过使用严重程度调整后的数据涉及这些DRG匹配的患者。在分析A中,研究组的死亡率降低了4.8%,每位患者的平均住院时间减少了16.5天,每位患者的可变直接成本减少了20,886美元。这些差异均无统计学意义。在分析B中,研究组患者的死亡率高1.2%(P = 0.741),每位患者的平均住院时间减少2.7天(P = 0.035),每位患者的可变直接成本减少2,626美元(P = 0.008)。在分析C中,研究组患者的死亡率低1.4%,每位患者的住院时间减少1.2天,每位患者的可变直接成本减少1,466美元。总之,该方案的实施带来了可观的成本节约。